Ann: China NMPA Approves Uscom BP Plus, page-34

Uscom sold a decent number of 1As in Australia 15 or so years ago. But even if Australian manufactured, selling into hospitals still costs time and money. The 1A is an expensive "nice to have" that requires specific training and education to convince doctors to use over the alternatives. In the 2000's UCM got the execs in with good resumes, had the partnerships and distributors and still failed commercially when targeting western countries.

Given basically all competitors have been taken over in the last 6 years and most were loss making it is somewhat astounding they've remained a going concern this long. It has only been possible by being lean and focusing most efforts on China. From experience they know competing with the big boys in established markets with a handful of products is doomed to failure.

Hopefully for those reasons the BP+ failed to sell with FDA and CE approval and the 1A success can be replicated with the BP+ in China.